A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

2014-08-27 03:13:16 | BioPortfolio


This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 in subjects with type 2 diabetes.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Diabetes Mellitus, Type 2


NN5401, NN5401, NN5401, biphasic insulin aspart 30, biphasic insulin aspart 30, biphasic insulin aspart 30






Novo Nordisk

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:13:16-0400

Clinical Trials [2816 Associated Clinical Trials listed on BioPortfolio]

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 in Japanese subjects with type 1 diabetes. Each subject will be...

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes

This trial is conducted in Asia and Japan. The aim of this clinical trial is to compare NN5401 with biphasic insulin aspart 30 in patients with type 2 diabetes not optimally controlled on ...

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

This trial is conducted in Europe. The aim of the trial is to compare two NN5401 formulations with each other and with biphasic insulin aspart 30, all in combination with metformin in insu...

Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue/intermediat...

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

This trial is conducted in Europe, Oceania and in the United States of America (USA). The aim of this clinical trial is to compare the long-term safety of NN5401 plus insulin aspart with ...

PubMed Articles [2066 Associated PubMed Articles listed on BioPortfolio]

Faster aspart insulin (FIASP®).

Fast-acting insulin aspart (faster aspart), commercialized under the trade name of Fiasp®, is insulin aspart in a new formulation aiming to mimic the physiologic prandial insulin release more closely...

In vitro assessment of the influence of intravenous extension set materials on insulin aspart drug delivery.

Insulin is a frequently prescribed drug in hospitals and is usually administered by syringe pumps with an extension line which can be made of various materials. Two insulin solutions were studied: an ...

Verification of Bioanalytical Method for Quantification of Exogenous Insulin (Insulin Aspart) by the Analyser Advia Centaur® XP.

In a number of cases the monitoring of patients with type I diabetes mellitus requires measurement of the exogenous insulin levels. For the purpose of a clinical investigation of the efficacy of a med...

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.

The majority of therapies have generally targeted fasting glucose control, and current mealtime insulin therapies have longer time action profiles than that of endogenously secreted insulin. The prima...

Insulin degludec/insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia independent of baseline HbAlevels, disease duration or BMI: A pooled meta-analysis of phase 3 studies in patients with type 2 diabetes.

Previous studies demonstrated the co-formulation of insulin degludec (IDeg)/insulin aspart (IAsp) 'IDegAsp' offers lower rates of hypoglycaemia with smaller changes in weight compared with basal-bolus...

Medical and Biotech [MESH] Definitions

An insulin preparation that is designed to provide immediate and long term glycemic control in a single dosage. Biphasic insulin typically contains a mixture of REGULAR INSULIN or SHORT-ACTING INSULIN combined with a LONG-ACTING INSULIN.

Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.

A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.

Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. It can be caused by the presence of INSULIN ANTIBODIES or the abnormalities in insulin receptors (RECEPTOR, INSULIN) on target cell surfaces. It is often associated with OBESITY; DIABETIC KETOACIDOSIS; INFECTION; and certain rare conditions. (from Stedman, 25th ed)

Insulin formulation containing substance which delays or retards time period of the absorption of insulin.

More From BioPortfolio on "A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes"

Quick Search


Searches Linking to this Trial